. 2021 Oct 9;36(3):772–780. doi: 10.1038/s41375-021-01442-8

Table 3.

PFS and OS up to 10 years after first rrHL.

	Group 1	Group 2	Group 3	Group 4	Group 5	Groups 3-5	Total
Progression-free survival
12 months	94.3% (79.0–98.5%)	78.6% (60.2–89.2%)	50.8% (32.4–66.6%)	86.7% (81.2–90.7%)	84.4% (72.9–91.3%)	82.3% (77.5–86.2%)	82.7% (78.6–86.1%)
24 months	88.4% (72.0–95.5%)	59.0% (40.0–73.8%)	43.6% (25.8–60.1%)	70.0% (63.0–76.0%)	67.1% (54.1–77.2%)	66.5% (60.7–71.6%)	67.7% (62.6–72.2%)
60 months	72.6% (53.7–84.8%)	36.2% (17.7–55.0%)	36.3% (19.7–53.2%)	61.1% (53.4–68.0%)	53.0% (39.7–64.6%)	56.6% (50.3–62.3%)	56.5% (51.0–61.6%)
120 months	72.6% (53.7–84.8%)	n.a.	31.3% (15.0–48.7%)	49.0% (39.6–57.7%)	48.5% (35.0–66.6%)	47.2% (40.1–53.9%)	48.2% (41.9–54.2%)
Overall survival
12 months	100.0% (100.0–100.0%)	81.7% (63.7–91.3%)	57.9% (39.3–72.7%)	93.6% (89.3–96.3%)	96.9% (88.1–99.2%)	90.5% (86.6–93.3%)	90.6% (87.3–93.1%)
24 months	94.1% (78.5–98.5%)	72.0% (53.0–84.4%)	47.8% (29.8–63.8%)	85.9% (80.2–90.0%)	85.9% (74.6–92.4%)	81.7% (76.8–85.7%)	82.4% (78.2–85.9%)
60 months	88.0% (71.2–95.3%)	43.8% (22.8–63.0%)	40.5% (23.2–57.1%)	73.3% (65.8–79.3%)	65.7% (52.3–76.2%)	68.0% (62.0–73.3%)	68.9% (63.6–73.6%)
120 months	81.8% (59.4–92.5%)	n.a.	40.5% (23.2–57.1%)	62.3% (53.0–70.3%)	55.6% (41.0–68.0%)	58.4% (51.2–64.9%)	59.4% (53.0–65.2%)

Group 1

Group 2

Group 3

Group 4

Group 5

Groups 3-5

Total

low risk

high age/comorbidty

salvage/stem cell failure

ASCT with watch & wait

ASCT with RT consolidation

ASCT intended

N = 36

N = 33

N = 38

N = 211

N = 66

N = 315

N = 409

Progression-free survival

12 months

94.3%

(79.0–98.5%)

78.6%

(60.2–89.2%)

50.8%

(32.4–66.6%)

86.7%

(81.2–90.7%)

84.4%

(72.9–91.3%)

82.3%

(77.5–86.2%)

82.7%

(78.6–86.1%)

24 months

88.4%

(72.0–95.5%)

59.0%

(40.0–73.8%)

43.6%

(25.8–60.1%)

70.0%

(63.0–76.0%)

67.1%

(54.1–77.2%)

66.5%

(60.7–71.6%)

67.7%

(62.6–72.2%)

60 months

72.6%

(53.7–84.8%)

36.2%

(17.7–55.0%)

36.3%

(19.7–53.2%)

61.1%

(53.4–68.0%)

53.0%

(39.7–64.6%)

56.6%

(50.3–62.3%)

56.5%

(51.0–61.6%)

120 months

72.6%

(53.7–84.8%)

n.a.

31.3%

(15.0–48.7%)

49.0%

(39.6–57.7%)

48.5%

(35.0–66.6%)

47.2%

(40.1–53.9%)

48.2%

(41.9–54.2%)

Overall survival

12 months

100.0%

(100.0–100.0%)

81.7%

(63.7–91.3%)

57.9%

(39.3–72.7%)

93.6%

(89.3–96.3%)

96.9%

(88.1–99.2%)

90.5%

(86.6–93.3%)

90.6%

(87.3–93.1%)

24 months

94.1%

(78.5–98.5%)

72.0%

(53.0–84.4%)

47.8%

(29.8–63.8%)

85.9%

(80.2–90.0%)

85.9%

(74.6–92.4%)

81.7%

(76.8–85.7%)

82.4%

(78.2–85.9%)

60 months

88.0%

(71.2–95.3%)

43.8%

(22.8–63.0%)

40.5%

(23.2–57.1%)

73.3%

(65.8–79.3%)

65.7%

(52.3–76.2%)

68.0%

(62.0–73.3%)

68.9%

(63.6–73.6%)

120 months

81.8%

(59.4–92.5%)

n.a.

40.5% (23.2–57.1%)

62.3%

(53.0–70.3%)

55.6%

(41.0–68.0%)

58.4%

(51.2–64.9%)

59.4%

(53.0–65.2%)

Kaplan–Meier estimates (95% confidence intervals).

ASCT high-dose chemotherapy and autologous stem-cell transplantation, PFS progression-free survival, OS overall survival, 95% CI confidence interval, n.a. not applicable.